Gastroenterology

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

The approval indicates linaclotide for pediatric patients ≥ 2 years of age with functional constipation, expanding its previous use in patients ≥ 6 years of age.

Kyle Staller, MD, MPH, explains new real-world data showing 41% of IBS-C patients change treatments at least once, with each switch driving higher HCRU and provider portal burden.

The FDA approved Abbreviated New Drug Applications from Lupin Pharmaceuticals for Famotidine Injection USP, 20 mg/2 mL (10 mg/mL), Single-Dose Vials.

Catch up on 5 notable studies and trial updates from DDW 2026!

Stay updated with the latest healthcare breakthroughs, including data from DDW and a new podcast episode.

Fukami, MD, discusses how first-line ESD may offer both survival and cost advantages over esophagectomy for EEC in the United States.

Chedid, MD, MS, explains the evolving therapeutic IBD landscape, including new data from DDW 2026.

Chedid describes the future of personalizing IBD care based on patient characteristics.

Catch up on new IBD drug trial data, regulatory actions, and updates in IBS in this April month in review.

Early data suggest varenicline may improve abdominal pain, bloating, and bowel symptoms in patients with IBS.

Colombel discusses long-term LUCENT extension data showing durable clinical, endoscopic, and histologic outcomes with mirikizumab in moderately to severely active UC.

Dellon explains phase 4 REMODEL trial data showing dupilumab’s impact on esophageal distensibility and the underlying remodeling process in eosinophilic esophagitis.

ICI colitis linked to high rehospitalization, ICU use, and mortality even after therapy discontinuation.

Despite a growing armamentarium of approved IBD therapies, outcomes remain suboptimal. Rubin explains how earlier treatment and smarter optimization can close the gap.

Laurent Peyrin-Biroulet, MD, PhD, breaks down FUZION data demonstrating meaningful fistula healing with guselkumab in Crohn’s disease patients with perianal disease.

Routine depression and anxiety screening in IBD clinics was tied to significantly more referrals and sustained follow-up with psychogastroenterology services

1-year results from ASPIRE-CD suggest risankizumab (Skyrizi) improves HRQL, well-being, and treatment satisfaction in adults with Crohn's Disease.

COBRA findings suggest 1 day of antibiotic treatment is preferred in acute cholangitis after adequate biliary drainage compared to longer guidelines.

Edward Barnes, MD, MPH, explains mirikizumab’s strong remission and durable response in Crohn’s disease patients after anti-TNF failure, supporting second-line use.

Maria Abreu, MD, breaks down efficacy and safety data for dual-target co-antibody JNJ-4804, offering a potential new option for heavily pretreated UC patients.